Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biosimilars & Generics

Set Alert for Biosimilars & Generics

‘In A Word, Complicated’ – AAM’s Burton Talks US Biosimilars

With the first US Humira rival having just hit the market and biosimilars seeing increasing adoption overall, Craig Burton – executive director of the AAM’s Biosimilars Council – says that the US biosimilars market is ‘doing better, but we still have improvements to make.’

Biosimilars Pricing Debate

Hitting A Moving Target: Teva’s Dethlefs Discusses US Complex Generics

With a number of US complex generic opportunities in Teva’s pipeline, the company’s executive vice president for North America commercial, Sven Dethlefs, talks about the challenges of bringing complex products to market against a backdrop of evolving FDA requirements.

Generic Drugs Regulation

Biosimilar Antibody-Drug Conjugates? Pfizer Isn’t Banking On It

Pfizer’s $43bn agreement to acquire Seagen would layer its portfolio and pipeline with vastly complex antibody-drug conjugates – a class of drug that execs feel might be almost immune to biosimilar competition. Generic firms’ history of frustration with ADCs suggests they may be right.

Biosimilars M & A

Biogen And Millennium May Be Ensnared In Tentacles Of Genentech’s Expired Cabilly Patent

Genentech claims Biogen and Millennium owe royalties on sales of Tysabri and Entyvio that were stockpiled when the Cabilly patent expired. Hospira faced similar litigation over its erythropoietin biosimilar and had to pay Amgen $70m in damages.

Intellectual Property Legal Issues

The Same But Different: Biden Budget Proposes Flexibility For Generic Drug-Device Combos, ‘Skinny Labels’

President Biden's fiscal year 2024 budget pushes new legislative changes to get generic drugs to market faster. 

Generic Drugs Legislation

Pink Sheet Podcast: State Of The Generics Industry, US FDA Adcomm Reforms, EUAs Outside COVID-19

Pink Sheet reporters and editor discuss learnings from a generic drug industry trade association conference, as well as FDA Commissioner Robert Califf’s ideas for advisory committee changes and using emergency use authorizations in non-COVID-19 areas.

Generic Drugs Advisory Committees

With Video Testimonial Campaign, Generics Industry Aims To Not Be Taken ‘4GRxANTED’

AAM hopes everyday voices – and Mark Cuban’s – will help policymakers appreciate the contributions that generic drugs make to the healthcare system. ‘We need to create an emotional connection,’ a campaign designer said.

Generic Drugs Lobbying

Finland Sees Progress On Biosimilar Substitution Plans

Updated plans to implement pharmacy-level biosimilar substitution in Finland have been published by a parliamentary health committee ahead of expected formal approval within weeks, reflecting certain industry criticisms that have now been taken on board.

Biosimilars Regulation

US FDA Set To Begin Training Patent Examiners This Spring

Prompted by an Executive Order on drug price competition, the cross-agency training aims to ensure that the Patent and Trademark Office is aware of all information that FDA makes available.

Legal Issues Intellectual Property

Can The Generics Industry Leverage Its COVID Success To Achieve Its Policy Goals?

Vaccine makers get all the credit (among those who think any credit is due) for ending the pandemic, but generic sponsors want to remind policymakers that their plants stayed open during the worst of COVID-19 to ensure that hospitals were stocked and medicines for chronic conditions didn’t run short.

Biosimilars Generic Drugs

Inflation, Biosimilars, And The Wizard Of Oz: An Interview With Teva’s Christine Baeder

The new chair of the US generics association talks to the Pink Sheet about how to make sure that policymakers don’t take the industry for granted.

Biosimilars Leadership
See All